Progress in the understanding of the biology and the treatment of multiple myeloma - A cure might be around the corner

被引：1
|
作者：
Mellstedt, H [1 ]
机构：
[1] Karolinska Hosp, Canc Ctr Karolinska, Radiumhemmet, Dept Oncol, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
来源：
ACTA ONCOLOGICA | 2000年 / 39卷 / 07期
关键词：
D O I：
10.1080/028418600750063460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：763 / 764
页数：2
相关论文
共 50 条
  • [41] Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma
    Yuan, Shihui
    Chen, Ying
    Liu, Huasheng
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [42] Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease
    Agarwal, Amit
    Ghobrial, Irene M.
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 985 - 994
  • [43] Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort
    Brioli, Annamaria
    Naegler, Theresa Maria
    Yomade, Olaposi
    Ruethrich, Maria Madeleine
    Scholl, Sebastian
    Frietsch, Jochen J. J.
    Hilgendorf, Inken
    Ernst, Thomas
    Sayer, Herbert Gottfried
    Hochhaus, Andreas
    Muegge, Lars-Olof
    von Lilienfeld-Toal, Marie
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (09) : 494 - 502
  • [44] Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 512 - 518
  • [45] Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (04) : 512 - 518
  • [46] Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
    Guerrero, Camila
    Puig, Noemi
    Cedena Romero, Maria Teresa
    Goicoechea, Ibai
    Burgos, Leire
    Alignani, Diego
    Lopez, Aitziber
    Sarvide, Sarai
    Jose Calasanz, Maria
    Garcia-Sanz, Ramon
    Martinez-Lopez, Joaquin
    Rosinol, Laura
    Gonzalez Garcia, Esther
    Oriol, Albert
    Rios, Rafael
    Carrillo-Cruz, Estrella
    Gonzalez Perez, Marta Sonia
    Montes Gaisan, Carmen
    De Arriba, Felipe
    Maria Arguinano, Jose
    Marti, Josep M.
    Gonzalez-Montes, Yolanda
    Garcia-Guinon, Antonio
    Lahuerta, Juan-Jose
    Blade Creixenti, Joan
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Paiva, Bruno
    BLOOD, 2022, 140
  • [47] Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents
    Abe, Masahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (04) : 307 - 309
  • [48] Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents
    Masahiro Abe
    International Journal of Hematology, 2011, 94 : 307 - 309
  • [49] Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm
    Vij, Ravi
    King, Justin
    Fiala, Mark A.
    Singh, Neeraj Kumar
    Sauban, Mohammed
    Husain, Zakir
    Lakshminarayana, Anjanasree V.
    Talawdekar, Anay Ashok
    Mitra, Upasana
    Abbasi, Taher
    Vali, Shireen
    BLOOD, 2018, 132
  • [50] From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma
    Mihaila, Romeo G.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2017, 12 (04) : 283 - 295
12345